IFNG and myeloid neoplasm: We have shown that our expanded NK cells, currently used in several clinical trials for myeloid malignancies and posterior fossa tumors (NCT01787474, NCT01904136, NCT01823198, NCT02271711), secrete large amounts of IFNγ compared to primary NK cells (8).